Less than 2 weeks after filing for an IPO, Translate Bio has secured a high-profile R&D partnership with Sanofi Pasteur, the vaccines unit of Sanofi, to develop next-generation mRNA vaccines for up to five undisclosed infectious disease pathogens. Formerly known as RaNA Therapeutics, Translate Bio acquired its mRNA therapy platform from Shire in 2016. For Sanofi, the deal follows a number of setbacks in the vaccine field and continues the company’s investment in mRNA technology after deals with CureVac and BioNTech.